14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PTCT vs MTVA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over MetaVia Inc. (MTVA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTCT carries a Unified Composite Score of 36.3/100 (SELL) at $56.42 (17.7x Forward P/E, 21.5% operating margin), whereas MTVA carries 48.0/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MTVA currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. PTCT 36.3/100 SELL), PTCT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. 0.0% operating margin) and revenue trajectory (+69.6% vs. +0.0% YoY).
Technical & Structure Timing Caution: PTCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile MTVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTCT vs MTVA. Trailing 12-month operating profitability (PTCT 21.5% vs MTVA 0.0%) and valuation multiples (PTCT 17.7x vs MTVA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PTCT vs MTVA Key Questions & Quantitative Answers
As of Nov 20, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over MetaVia Inc. (MTVA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTCT carries a Unified Composite Score of 36.3/100 (SELL) at $56.42 (17.7x Forward P/E, 21.5% operating margin), whereas MTVA carries 48.0/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTVA currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. PTCT 36.3/100 SELL), PTCT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. 0.0% operating margin) and revenue trajectory (+69.6% vs. +0.0% YoY). Technical & Structure Timing Caution: PTCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile MTVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PTCT leads the Growth & Scale pillar: PTCT posts +69.6% YoY revenue growth and +0.0% YoY earnings growth on $1.16B TTM revenue (55.2% gross margin, 21.5% operating margin), compared with MTVA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PTCT generates $1.16B in USD-normalized revenue versus N/A for MTVA. In operating R&D and SG&A reinvestment, PTCT deploys 33.7% of Rev ($389M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTVA.
PTCT screens cheaper on headline valuation multiples. PTCT trades at 17.7x Forward P/E, 18.0x Trailing P/E, 0.81x PEG, and 4.3x EV/Revenue (-3.6% FCF margin), whereas MTVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTCT (-7740.1% ROE) versus MTVA (-175.7% ROE) capital efficiency.
In options market volatility and institutional positioning, PTCT carries 52.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 58% Vol realized risk). By comparison, MTVA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.30β · 166% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.